{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:18:40Z","timestamp":1785377920243,"version":"3.55.0"},"reference-count":107,"publisher":"Wiley","issue":"S4","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Recent technological innovations in haemophilia have advanced at an astounding pace, including gene therapy programmes and bioengineered molecules for prophylaxis, products that reduce treatment burden through half\u2010life extension, unique mechanisms of action, and subcutaneous administration. Additional technological advancements have emerged that are anticipated to further transform haemophilia care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Review new and emerging haemophilia therapies, including replacement and bypassing products, digital applications, utilisation of big data, and personalised medicine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were obtained from peer\u2010reviewed presentations\/publications, and ongoing studies in haemophilia, ultrasonography, and artificial intelligence (AI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Available treatments include new recombinant factors VIII (FVIII) and IX (FIX), extended half\u2010life FVIII\/IX products, a new FVIIa product for inhibitor patients, and a FVIIIa\u2010mimetic. Several novel therapeutics are in clinical trials, including FVIIIa mimetics and inhibitors of naturally\u2010occurring anticoagulants. Ongoing gene therapy trials suggest that a single vector infusion using an optimised construct can produce factor activity that reduces bleeding to near zero for years. Today, persons with haemophilia (PwH) approach a lifespan comparable to that of the general population, presenting treatment challenges for age\u2010related co\u2010morbidities. Technological innovations have broadened beyond therapeutics to include large database analyses utilising remote data collection with handheld devices, and to tailor AI applications. Current development efforts include patient\u2010performed ultrasonography, algorithms for scan interpretation, and point\u2010of\u2010care haemostatic testing devices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We have entered a golden age for haemophilia treatment and care with wide\u2010ranging advancements targeting improved quality of life (QoL). Future\u2010focused efforts by clinical and patient communities may provide equitable access and care for people impacted by haemophilia worldwide.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14531","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T06:07:08Z","timestamp":1651817228000},"page":"77-92","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Therapeutic and technological advancements in haemophilia care: Quantum leaps forward"],"prefix":"10.1111","volume":"28","author":[{"given":"Magdalena","family":"Lewandowska","sequence":"first","affiliation":[{"name":"Indiana Hemophilia &amp; Thrombosis Center, Inc.  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Nasr","sequence":"additional","affiliation":[{"name":"GLOVAL LLC  Broomfield Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Indiana Hemophilia &amp; Thrombosis Center, Inc.  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3283367931"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000187250.32630.56"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12531"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb03856.x"},{"issue":"2","key":"e_1_2_9_7_1","first-page":"437","article-title":"Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators","volume":"96","author":"Soucie JM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1050"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-05-0407"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13616"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26018"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232132"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3757.3757"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15259"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.SCI-9.SCI-9"},{"key":"e_1_2_9_19_1","unstructured":"MahlanguJ LevyH KhacchatryanM et\u00a0al.Phase 2\/3 trial of subcutaneous engineered FVIIa Marzeptacog Alfa (activated) in hemophilia A or B with inhibitors: pharmacokinetics efficacy and safety.Paper presented at: ISTH 2019 Congress;Melbourne Au."},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.16039.1","article-title":"Merging into the mainstream: the evolution of the role of point\u2010of\u2010care musculoskeletal ultrasound in hemophilia","volume":"8","author":"Bakeer N","year":"2019","journal-title":"F1000Res"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13163"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14006"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13088"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-11-0874"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jum.14846"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2019.07.018"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.15.14981"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14242"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13429"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13269"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12622"},{"key":"e_1_2_9_32_1","first-page":"1","article-title":"Teleguidance enables patient self\u2010imaging of arthropathic joints using mobile ultrasound devices","volume":"27","author":"Aguero P","year":"2021","journal-title":"Haemophilia"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12305"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2014.00180"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.099069"},{"key":"e_1_2_9_36_1","volume-title":"Treatment Options in the Management of Haemophilia in Developing Countries","author":"Chandy M","year":"2005"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","unstructured":"AdamopoulouE MoussiadesL.An overview of chatbot technology. Artificial intelligence applications and innovations.Paper presented at: 16th IFIP WG 12.5 International Conference 2020;Neos Marmaras Greece.","DOI":"10.1007\/978-3-030-49186-4_31"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2196\/26911"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14040"},{"key":"e_1_2_9_40_1","unstructured":"Artificial intelligence to improve QoL for people with haemophilia in Africa.https:\/\/nnhf.org\/artificial-intelligence-to-improve-quality-of-life-for-people-with-haemophilia-in-africa\/. Accessed November 18 2021."},{"key":"e_1_2_9_41_1","unstructured":"TyrrellP BV MendezM PaniukovD BrandB ZakM RothJ.Detection of joint effusions in pediatric patients with hemophilia using artificial intelligence\u2010assisted ultrasound scanning; early insights from the development of a self\u2010management tool.Paper presented at: ISTH;2021;Philadelphia PA."},{"key":"e_1_2_9_42_1","unstructured":"ATHN.https:\/\/athn.org\/what-we-do\/overview.html. Accessed December 17 2021."},{"key":"e_1_2_9_43_1","volume-title":"Artificial Intelligence and Machine Learning","author":"Rogers B","year":"2021"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.03.002"},{"key":"e_1_2_9_45_1","unstructured":"Manco\u2010JohnsonM BrionesN TranA et\u00a0al.Emicizumab: will it suffice for bone metabolism?Paper presented at: ISTH Virtual Congress;2021:Philadelphia."},{"key":"e_1_2_9_46_1","volume-title":"Underlying Cause of Death, 1999\u20132018. CDC WONDER Online Database","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14305"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_99"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12746"},{"key":"e_1_2_9_51_1","unstructured":"Ter\u2010ZakarianAABK BarnesR&vonDrygalskiAPrevalence of hypertension in hemophilia patients: a systematic review [abstract]. 2021;https:\/\/abstracts.isth.org\/abstract\/prevalence-of-hypertension-in-hemophilia-patients-a-systematic-review\/. Accessed 17 November 2021."},{"key":"e_1_2_9_52_1","volume-title":"Prevalence of Obesity among Adults and Youth: United States, 2015\u20132016","author":"National Center For Health Statistics"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01183.x"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-6556-7"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00431.x"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v9i11.2579"},{"key":"e_1_2_9_57_1","unstructured":"Fitusiran update following EAHAD 2021 Congress [press release].2021.https:\/\/www.ehc.eu\/joint-statement-on-fitusiran-update-following-eahad-2021-congress\/. Accessed 20 March 2022."},{"key":"e_1_2_9_58_1","doi-asserted-by":"crossref","unstructured":"SeremetisS CepoK RasmussenJ et\u00a0al.Risk mitigation strategy for concizumab clinical trials after pause due to non\u2010fatal thrombotic events.62nd ASH Annual Meeting and Exposition;2020.","DOI":"10.1182\/blood-2020-139563"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13822"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12468"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14403"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15397"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb08114.x"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02739.x"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075760"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.384.384"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02429.x"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612943"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_2_9_71_1","volume-title":"Recombinate (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2018"},{"key":"e_1_2_9_72_1","volume-title":"Kogenate FS with Vial Adapter (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2016"},{"key":"e_1_2_9_73_1","volume-title":"Advate (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2018"},{"key":"e_1_2_9_74_1","volume-title":"Novoeight (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_75_1","volume-title":"Xyntha (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_76_1","volume-title":"Kovaltry (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2021"},{"key":"e_1_2_9_77_1","volume-title":"Nuwiq (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_78_1","volume-title":"Eloctate (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_79_1","volume-title":"Adynovate (Antihemophilic Factor [Recombinant (Pegylated)]) [Prescribing Information]","year":"2021"},{"key":"e_1_2_9_80_1","volume-title":"Afstyla (Antihemophilic Factor [Recombinant]) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_81_1","volume-title":"Jivi (Antihemophilic Factor [Recombinant (Pegylated)]) [Prescribing Information]","year":"2018"},{"key":"e_1_2_9_82_1","volume-title":"Esperoct (Antihemophilic Factor [Recombinant (Pegylated)]) [Prescribing Information]","year":"2019"},{"key":"e_1_2_9_83_1","unstructured":"U.S. National Library of Medicine.https:\/\/clinicaltrials.gov\/. Accessed 17 December 2021."},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001292"},{"key":"e_1_2_9_85_1","unstructured":"Safety and pharmacokinetics of subcutaneous injection of OCTA101 in adult patients with severe hemophilia A.https:\/\/ClinicalTrials.gov\/show\/NCT04046848. Accessed 21 December 2021."},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000999"},{"key":"e_1_2_9_87_1","volume-title":"Hemlibra (Emicizumab\u2010kxwh) [Prescribing Information]","year":"2021"},{"key":"e_1_2_9_88_1","doi-asserted-by":"crossref","unstructured":"LeavittAD KonkleBA StineK et\u00a0al.Updated follow\u2010up of the Alta Study a phase 1\/2 Study of Giroctocogene Fitelparvovec (SB\u2010525) gene therapy in adults with severe hemophilia A.Paper presented at: Blood2020;2020.","DOI":"10.1182\/blood-2020-137648"},{"key":"e_1_2_9_89_1","first-page":"221","article-title":"Recent advances in the treatment of hemophilia: a review","volume":"15","author":"Marchesini E","year":"2021","journal-title":"Biologics"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14391"},{"key":"e_1_2_9_91_1","volume-title":"BeneFIX [Coagulation Factor IX (Recombinant)] [Prescribing Information]","year":"2021"},{"key":"e_1_2_9_92_1","volume-title":"Rixubis [Coagulation Factor IX (Recombinant)] [Prescribing Information]","year":"2014"},{"key":"e_1_2_9_93_1","volume-title":"Ixinity [Coagulation Factor IX (Recombinant)][Prescribing Information]","year":"2021"},{"key":"e_1_2_9_94_1","volume-title":"Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_95_1","volume-title":"Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] [Prescribing Information]","year":"2021"},{"key":"e_1_2_9_96_1","volume-title":"Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) Lyophilized Powder for Solution for Intravenous Injection","year":"2017"},{"key":"e_1_2_9_97_1","unstructured":"van derFlierA IsmailA MooreN et\u00a0al.The pharmacokinetic profiles of intravenously and subcutaneously administered recombinant factor IX Fc\u2010XTEN in Cynomolgus Monkeys.ISTH Annual Congress;2017."},{"key":"e_1_2_9_98_1","unstructured":"MahlanguJ LevyH NegrierC.Phase 2b trial to evaluate the safety & factor IX levels resulting from a daily subcutaneously prophylaxis treatment regimen of dalcinonacog Alfa in haemophilia B.Paper presented at: 13th Annual Congress of European Association for Haemophilia and Allied Disorders;2020:The Hague The Netherlands."},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.05.038"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15244"},{"key":"e_1_2_9_103_1","volume-title":"SerpinPC is Safe and Reduces Bleeding in Persons with Severe Haemophilia (PsH) in a Single Ascending Dose (SAD) Study \u2010 AAP\u20100101","author":"Baglin T","year":"2021"},{"issue":"15","key":"e_1_2_9_104_1","first-page":"9","article-title":"An engineered factor Va prevents bleeding induced by direct\u2010acting oral anticoagulants by different mechanisms","volume":"4","author":"Drygalski ABV","year":"2020","journal-title":"Blood Adv"},{"key":"e_1_2_9_105_1","volume-title":"(Factor VIIa) [Prescribing Information]","author":"NovoSeven RT","year":"2020"},{"key":"e_1_2_9_106_1","volume-title":"SevenFact (Factor VIIa [Recombinant]\u2010jncw) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_107_1","volume-title":"FEIBA (Anti\u2010Inhibitor Coagulant Complex) [Prescribing Information]","year":"2020"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00450.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T09:43:53Z","timestamp":1698831833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":107,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/hae.14531"],"URL":"https:\/\/doi.org\/10.1111\/hae.14531","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2022-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}